ARRIA Study: Abatacept vs PBO in pre-clincial RA (N98) pts x 6 mos. Showed ABA prevented arthritis (8 vs 35%), improved MRI inflamm (61 v 31%), fewer D/C (14 vs 43%) - all signif. Further FUV 12 mos off therapy still significant at 18mos #ACR21 Abstract 0455 https://t.co/ZxFUj6KfLT